malaymail.com 03 May, 2021 12:15 am

Duopharma Biotech’s Q1 net profit increases to RM17.6m

Duopharma Biotech’s Q1 net profit increases to RM17.6m
KUALA LUMPUR, May 3 — Duopharma Biotech Bhd’s net profit for the first quarter (Q1) ended March 31, 2021 increased to RM17.61 million from RM13.56 million in the same period last year. Revenue increased to RM166.45 million from RM158.71 million previously mainly due to higher sales to the...

KUALA LUMPUR, May 3 — Duopharma Biotech Bhd’s net profit for the first quarter (Q1) ended March 31, 2021 increased to RM17.“The supply is subject to the execution of the definitive supply agreements between Russian Direct Investment Fund and Duopharma Biotech and between MoH and Duopharma Biotech as well as the approval of the vaccine by the Drug Control Authority, Malaysia.On prospects, it said the company has recently extended two contracts comprising the supply and delivery of human insulin products worth RM19.It said the company has also entered into a term sheet agreement with the Ministry of Health (MoH) to supply 6.

“Pending the execution and signing of definitive supply agreements and conditional registration approval by the Drug Control Authority, the management of vaccine supply is expected to contribute positively to the future earnings of Duopharma for the financial year ending Dec 31, 2021,” it added.56 million in the same period last year.

Read full story at malaymail.com